These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16421910)

  • 1. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.
    Ramanujachar R; Richards S; Hann I; Goldstone A; Mitchell C; Vora A; Rowe J; Webb D
    Pediatr Blood Cancer; 2007 Mar; 48(3):254-61. PubMed ID: 16421910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
    Hann I; Vora A; Richards S; Hill F; Gibson B; Lilleyman J; Kinsey S; Mitchell C; Eden OB
    Leukemia; 2000 Mar; 14(3):356-63. PubMed ID: 10720126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
    Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
    Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
    Brisco J; Hughes E; Neoh SH; Sykes PJ; Bradstock K; Enno A; Szer J; McCaul K; Morley AA
    Blood; 1996 Jun; 87(12):5251-6. PubMed ID: 8652840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
    Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
    Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
    Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR
    Blood; 1995 Apr; 85(8):2025-37. PubMed ID: 7718875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
    Horibe K; Yumura-Yagi K; Kudoh T; Nishimura S; Oda M; Yoshida M; Komada Y; Hara J; Tawa A; Usami I; Tanizawa A; Kato K; Kobayashi R; Matsuo K; Hori H;
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):81-89. PubMed ID: 28169879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.
    Lawson SE; Harrison G; Richards S; Oakhill A; Stevens R; Eden OB; Darbyshire PJ
    Br J Haematol; 2000 Mar; 108(3):531-43. PubMed ID: 10759711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia.
    Henze G; Fengler R; Reiter A; Ritter J; Riehm H
    Haematol Blood Transfus; 1990; 33():483-8. PubMed ID: 2182441
    [No Abstract]   [Full Text] [Related]  

  • 12. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
    Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
    Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
    Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
    Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (greater than 100/nl) with rotation of non-cross-resistant drug combinations.
    Janka-Schaub GE; Goebel U; Graubner U; Haas RJ; Juergens H; Spaar HJ; Winkler K
    Haematol Blood Transfus; 1990; 33():489-93. PubMed ID: 2182442
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
    Parker C; Waters R; Leighton C; Hancock J; Sutton R; Moorman AV; Ancliff P; Morgan M; Masurekar A; Goulden N; Green N; Révész T; Darbyshire P; Love S; Saha V
    Lancet; 2010 Dec; 376(9757):2009-17. PubMed ID: 21131038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
    Rytting ME; Thomas DA; O'Brien SM; Ravandi-Kashani F; Jabbour EJ; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Cortes JE; Borthakur G; Garris R; Cardenas-Turanzas M; Schroeder K; Jorgensen JL; Kornblau SM; Kantarjian HM
    Cancer; 2014 Dec; 120(23):3660-8. PubMed ID: 25042398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies.
    Niehues T; Kapaun P; Harms DO; Burdach S; Kramm C; Körholz D; Janka-Schaub G; Göbel U
    Leukemia; 1999 Apr; 13(4):614-7. PubMed ID: 10214870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial.
    Roy A; Bradburn M; Moorman AV; Burrett J; Love S; Kinsey SE; Mitchell C; Vora A; Eden T; Lilleyman JS; Hann I; Saha V;
    Br J Haematol; 2005 Apr; 129(1):35-44. PubMed ID: 15801953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.